ISRCTN45127327已完成未知
Efficacy of memantine in the treatment of fibromyalgia: a double-blind randomised controlled trial
Aragon Institute of Health Sciences (Instituto Aragonés de Ciencias de la Salud) (IACS) (Spain)0 个研究点目标入组 60 人开始时间: 2012年8月3日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
- 2013 protocol in: http://www.ncbi.nlm.nih.gov/pubmed/23286311 2. 2014 results in https://www.ncbi.nlm.nih.gov/pubmed/25218600 (added 21/01/2019)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Male or female aged between 18 and 65 years
- •2. Ability to understand Spanish
- •3. Diagnosis of fibromyalgia carried out by a rheumatologist according to the American College of rheumatology criteria (ACR1990)
- •4. Ability to read and understand the Patient Information Sheet
- •5. Signature of Informed Consent Form
- •6. In the case of women of childbearing age, commitment not to become pregnant during the entire duration of the study
排除标准
- •1. Undergoing drug treatment for fibromyalgia. Patients in current treatment for fibromyalgia will stop treatment and perform a washout period of one week. During that week the patient may take, if necessary, analgesics such as tramadol or paracetamol to minimise the influence of medication on brain imaging.
- •2. Currently taking memantine or having taken memantine during the 2 months prior to recruitment
- •3. Another Axis I psychiatric disorder using Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) that might hinder adherence to the protocol (e.g.: dementia, alcohol and/or substance abuse/dependence, schizophrenia, chronic delirium, acute depression)
- •4. Pregnancy or breast-feeding
- •5. Hypersensitivity to the active ingredient, memantine, or to the excipients
- •6. Medical conditions that require special precautions when administering memantine according to the summary of product characteristics:
- •6.1. Epilepsy
- •6.2. Circumstances that may cause high urine pH owing to Proteus urinary infection, renal tubular acidosis or vegetarian diet, recent myocardial infarction, congestive heart disease and uncontrolled arterial hypertension
- •7. Clinically significant and active evidence of liver or kidney disease, haematological, respiratory, endocrine or cardiovascular disease or disorders (patients with controlled diabetes and patients with controlled hypertension and complete or incomplete right bundle branch block can be included in the study)
- •8. Use of prescription drugs that may cause relevant drug interactions with memantine according to the summary of product characteristics: NMDAR antagonists (amantadine, ketamine, dextromethorphan), L-Dopa, dopamine agonists and cholinergic agonists.
- •9. Use of non-permitted concomitant medication during the week prior to the first evaluation visit or where the patient is expected to require treatment (with at least one of the drugs not permitted during the study): antidepressants (duloxetine, venlafaxine, mirtazapine, bupropion, SSRI, etc.), analgesics (pregabalin, gabapentin, opiates, etc.)
研究者
相似试验
进行中（未招募）
不适用
Study of the efficacy of the drug memantine in the treatment of fibromialgiaFibromialgiaMedDRA version: 14.0Level: PTClassification code 10048439Term: FibromyalgiaSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2011-000802-23-ESJavier García Campayo
Unknown
3 期
Randomised Controlled Trial of Memantine in FibromyalgiaFibromyalgiaNCT01653457Aragon Institute of Health Sciences60
已完成
不适用
Investigation on efficacy of memantine in patients with Alzheimer's disease.s diseaseAlzheimer's diseaseJPRN-UMIN000011392Kawasaki Medical School50
已完成
不适用
Memantine Treatment in Fragile X-Associated Tremor/Ataxia SyndromeFragile X-Associated Tremor/Ataxia SyndromeFragile X Premutation CarriersNCT00584948University of California, Davis94
终止
2 期
Memantine for Recurrent GlioblastomaGlioblastomaNCT01260467University of Rochester4